GE Healthcare is sponsoring a series of multicenter trials to validate the clinical efficacy of its LightSpeed VCT 64-slice CT system as a method for the diagnosis and treatment planning of cardiovascular disease, according to the Chalfont St. Giles, U.K.-based firm.
The intent of the trials is to determine what role the VCT can play in minimizing noninterventional catheterization, as well as how it can be used to improve the early diagnosis of otherwise occult coronary artery disease, the company said.
The trial will not only seek to clinically validate the use of CT for noninvasive diagnosis of coronary artery disease, but will also examine patient results and analyze changes in the cardiologist's decision-making process and patient management, GE said.
Patient enrollment began this month and the firm said that it expects results to be published next year.
By AuntMinnie.com staff writers
March 15, 2006
Related Reading
GE inks healthcare IT deal with USFPG, March 15, 2006
GE receives Innova 510(k) clearance, March 14, 2006
GE adds to cardiac line, March 14, 2006
GE, St. Joseph's ink research deal, March 8, 2006
GE, Olympic Committees perform cardiac research, February 20, 2006
Copyright © 2006 AuntMinnie.com
